Ribociclib (Kisqali®) in combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.
|Rapid Review Process||Complete|
|Rapid review received||04/09/2017|
|Rapid review completed||19/09/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|